The MattCorc Podcast: Recent Episodes
Life Sciences Rush Hour - Inve
A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email.
We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.
GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.
I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.
Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.
Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.
How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.
An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.
With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?
A ton was learned at the MWE life science deal making symposium and here I share that with you.
A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.
What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.
I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.
Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.
A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.
A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs
A quick synopsis of how insurance liability changes as a company enters the realm to an FDA regulated product.
Where to look for additional coverage in your proprty policy above and beyond replacing your building or contents. Things to be aware of that could reduce coverage.
I discuss the Abbvie testosterone settlement and the role of product liability insurance could play. Hurricanes and property insurance.
A recap of Boston Biotech Week and the RESI conference. How insurance can help you stand out with investors.
A discussion on Product Liability insurance in relation to a possible opioid settlement. Wage & Hour lawsuits are on the rise but there is a solution.
In the wake of an API manufacturer being shut down in China I discuss using insurance to mitigate the cash flow disruption.
The possible impacts on moving from quarterly to semiannual reporting periods for public companies on the D&O insurance marketplace
Amicus and Alnylam both got FDA approval last week. Find out how that can change their risk profile.
I discuss the PGA Championship being cyber extorted, CA Consumer Privacy Act and the role insurance plays in both of these events.
We discuss Apple hitting the $1 trillion mark, AIG going the other way, government taking your patent and D&O insurance
I talk about the prevalence of securities class action filings and how D&O can protect you. I also discuss how we should not choose limits solely by what our peers have in place.
I talk about what we can learn from Sarepta's clinical hold and how they could insure such an event for their commercial product.
Today we are reminded, due to the news that Keryx and Akebia are merging, of what happens when you have a supply chain issue.
Recap of today’s big events. Stryker bidding on Boston Scientific. CRISPR might cause cancer.
I discuss liability when a digital health product works but something bad happens. Blurring the lines of medtech and digital health.
IPO market is healthy. Rockwell Medical and how D&O insurance could provide balance sheet protection
Keytruda does it again in the clinic and also changes to M&A landscape. What’s going on at Rockwell Medical? Is your product temperature sensitive?
Quick rundown on FDA related news, Hemophilia news and how right to try could impact the insurance market